Our objective was to assess the utility of the addition of delayed latent type hypersensitivity antigens (anergy testing) to purified protein derivative (PPD) tuberculin skin testing on intake to a correctional facility. We conducted a retrospective review of a two and a half year period during which new inmates were skin tested with PPD, Candida albicans, and mumps antigens by the Mantoux method. Of the 11,514 tested, 7.0 percent had prior PPD positive test results, 4.2 percent were new PPD positive, and 6.6 percent were anergic. HIV prevalence was 6 percent. Three active cases of tuberculosis were found. No benefit from anergy skin testing was found in this jail population.
Get full access to this article
View all access options for this article.
References
1.
AllandD., KalkutG., MossA., McAdamR., HahnJ., BosworthW., DruckerE., & BloomB. (1994). Transmission of tuberculosis in New York City: An analysis by DNA fingerprinting and conventional epidemiologic methods. The New England Journal of Medicine, 330(24), 1710-1716.
2.
American Thoracic Society (ATS)/Centers for Disease Control and Prevention (CDC). (1992). Control of tuberculosis in the United States. American Review of Respiratory Diseases, 146, 1623-1633.
3.
BellinE., FletcherD., & SayferS. (1993). Abnormal chest X-rays in intravenous drug users: Implications for tuberculosis screening programs. American Journal of Public Health, 83(5), 698-700.
4.
BirxD., BrundageJ., LarsonK., EnglerR., SmithL., SquireE., CarpenterG., SullivanM., RhoadsJ., OsterC., JamesW., LuptonC., WierzbaT., BurkeD., RedfieidR., & the Military Medical Consortium for Applied Retroviral Research. (1993). Journal of Acquired Immunodeficiency Syndrome, 6, 1248-1257.
5.
CaiaffaW., GrahamM., GalaiN., RizzoR., NelsonK., & VlahovD. (1995). Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection. Archives of Internal Medicine, 155, 2111-2117.
6.
Centers for Disease Control and Prevention. (1991, 26 April). Purified protein derivative (PPD) - tuberculin anergy and HIV infection: Guidelines for anergy testing and management of anergic persons at risk of tuberculosis. Morbidity and Mortality Weekly Report. 40 (RR-5).
7.
Centers for Disease Control and Prevention. (1995, 8 September). Essential components of a tuberculosis prevention and control program; and Screenings for tuberculosis and tuberculosis infection in high-risk populations: Recommendations of the Advisory Council for the Elimination of Tuberculosis. Morbidity and Mortality Weekly Report. 44 (RR-1 1).
8.
Centers for Disease Control and Prevention. (1996, 7 June). Prevention and control of tuberculosis in correctional facilities: Recommendations of The Advisory Council for the Elimination of Tuberculosis. Morbidity and Mortality Weekly Report. 45 (RR-5).
9.
ChinD., OsmondD., Page-ShaferK., GlassrothJ., RosenM., ReichmanL., KualeP., WallaceJ., PouleW., & HopewellP. (1996). Reliability of anergy skin testing in persons with HIV infection. The Pulmonary Complications of HIV Infection Study Group. American Journal of Respiratory & Critical Care Medicine, 153(6 Pt 1), 1982-1984.
10.
DolanM., ClericiM., BlattS., HendrixC., MelcherC., BoswellN., FreemanT., WardW., HensleyR., & SheaverC. (1995). Invitro T cell function, delayed-type hypersensitivity, and CD4 + T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. The Journal of Infectious Diseases, 172, 79-87.
11.
GordinF., MattsJ., MillerC., BrownL., & El-SadrW., (1996). A prospective, double-blind, placebo-controlled trial of isoniazid for prevention of tuberculosis in anergic HIV-infected patients at high risk for tuberculosis. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract LB1 1.
12.
HammettT., & HarroldL. (1994). Tuberculosis in correctionalfacilities. Washington, D.C.: U.S. Department of Justice.
HuebnerR., ScheinM., HallC., & BanesS. (1994). Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with Mycobacterium tuberculosis. Clinical Infectious Diseases, 19, 26-32.
15.
JordanT., LewitE., MontgomeryR., & ReichmanL. (1991). Isoniazid as preventive therapy in HIV-infected intravenous drug users. Journal of the American Medical Association, 265(22), 2987-2991.
MarkowitzN., HansenN., HopewellP., GlassrothJ., KvaleP., ManguraB., WilcoskyT., WallaceJ., RosenM., LeichmanL., & the Pulmonary Complications of HIV Infection Study Group. (1997). Incidence of tuberculosis in the United States among HIV-infected persons. Annals of Internal Medicine, 126(2), 123-132.
18.
MorenoS., Baraia-EtxaburuJ., BaizaE., ParraF., Perez-TasconM., MirallesP., VicenteT., AlberdiJ., CosinJ., & Lopez-GayD. (1993). Risk of developing tuberculosis among anergic patients infected with HIV. Annals of Internal Medicine, 119(3), 194-198.
19.
NashD., & DouglassJ. (1980). Anergy in active pulmonary tuberculosis: A comparison between positive and negative reactors and an evaluation of 5 TU and 250 TU skin test doses. Chest, 77, 32-37.
20.
National Commission on Correctional Health Care. (1996, Spring). Position Statement. Management of tuberculosis in correctional facilities. Journal of Correctional Health Care, 3(1), 97-102.
21.
PesantiE. (1994). The negative tuberculin test: Tuberculin, HIV, and anergy panels. American Journal of Respiratory and Critical Care Medicine, 149, 1699-1709.
22.
RoseD., SchecterC., & SacksH. (1992). Preventive medicine for HIV-infected patients: An analysis of isoniazid prophylaxis for tuberculin reactors and for anergic patients. Journal of General Internal Medicine, 7, 589-594.
23.
SelwynP., HartelD., & LewisV. (1989). A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. New England Journal of Medicine, 320, 545-550.
24.
SelwynP., SckellB., AlcabesP., FriedlandC., KleinR., & SchoenbaumE. (1992). High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. Journal of the American Medical Association, 268(4), 504-507.
25.
SteadW. (1978). Undetected tuberculosis in prison: Source of infection for community at large. Journal of the American Medical Association, 440(23), 2544-2547.
26.
VillarinoM., GeiterL., SchulteJ., & CastroK. (1994). Purified protein derivative tuberculin and delayed-type hypersensitivity skin testing in migrant farm workers at risk for tuberculosis and HIV coinfection. AIDS, 8(4), 477-481.
